Scarica l'app Stockscreener
146.99
0.99%
1.44
Pre-mercato:
146.74
-0.25
-0.17%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ILMN Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$145.55
Aprire:
$150
Volume 24 ore:
2.29M
Relative Volume:
1.31
Capitalizzazione di mercato:
$22.46B
Reddito:
$4.28B
Utile/perdita netta:
$1.26B
Rapporto P/E:
18.62
EPS:
7.8957
Flusso di cassa netto:
$943.00M
1 W Prestazione:
-0.08%
1M Prestazione:
+8.99%
6M Prestazione:
+48.10%
1 anno Prestazione:
+1.92%
Intervallo 1D:
$142.53
$151.00
Intervallo di 1 settimana:
$139.79
$151.34
Portata 52W:
$68.70
$153.06
Illumina Inc Stock (ILMN) Company Profile
Nome
Illumina Inc
Settore
Industria
Telefono
(858) 202-4500
Indirizzo
5200 ILLUMINA WAY, SAN DIEGO, CA
Confronta ILMN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ILMN
Illumina Inc
|
146.99 | 22.24B | 4.28B | 1.26B | 943.00M | 7.8957 |
|
TMO
Thermo Fisher Scientific Inc
|
607.08 | 231.23B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
235.56 | 168.82B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
714.04 | 57.87B | 4.17B | 1.03B | 940.22M | 12.61 |
|
A
Agilent Technologies Inc
|
146.32 | 41.95B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
IQV
Iqvia Holdings Inc
|
241.57 | 41.02B | 15.90B | 1.28B | 2.21B | 7.2842 |
Illumina Inc Stock (ILMN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-12 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2025-07-11 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| 2025-03-04 | Reiterato | Citigroup | Neutral |
| 2025-02-28 | Downgrade | HSBC Securities | Buy → Hold |
| 2025-02-10 | Downgrade | Barclays | Equal Weight → Underweight |
| 2025-02-07 | Downgrade | TD Cowen | Buy → Hold |
| 2024-12-11 | Downgrade | Citigroup | Buy → Neutral |
| 2024-11-12 | Ripresa | Morgan Stanley | Equal-Weight |
| 2024-10-17 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-08-28 | Aggiornamento | Argus | Hold → Buy |
| 2024-08-16 | Aggiornamento | Daiwa Securities | Neutral → Buy |
| 2024-08-14 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2024-08-14 | Aggiornamento | TD Cowen | Hold → Buy |
| 2024-07-10 | Aggiornamento | Citigroup | Neutral → Buy |
| 2024-06-03 | Ripresa | Jefferies | Hold |
| 2024-01-16 | Downgrade | HSBC Securities | Buy → Hold |
| 2024-01-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-12-18 | Aggiornamento | Scotiabank | Sector Perform → Sector Outperform |
| 2023-12-15 | Aggiornamento | Bernstein | Underperform → Mkt Perform |
| 2023-12-14 | Iniziato | Guggenheim | Buy |
| 2023-12-14 | Iniziato | Stephens | Overweight |
| 2023-12-13 | Iniziato | Wolfe Research | Outperform |
| 2023-12-12 | Downgrade | BofA Securities | Neutral → Underperform |
| 2023-12-11 | Aggiornamento | Citigroup | Sell → Neutral |
| 2023-11-10 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2023-09-28 | Iniziato | Bernstein | Underperform |
| 2023-07-05 | Ripresa | JP Morgan | Neutral |
| 2023-01-25 | Downgrade | Argus | Buy → Hold |
| 2023-01-05 | Iniziato | Scotiabank | Sector Perform |
| 2022-12-12 | Downgrade | Citigroup | Neutral → Sell |
| 2022-12-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2022-10-04 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2022-09-28 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2022-08-25 | Iniziato | Credit Suisse | Neutral |
| 2022-07-13 | Downgrade | Barclays | Equal Weight → Underweight |
| 2022-01-18 | Aggiornamento | Stifel | Hold → Buy |
| 2022-01-11 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2022-01-07 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-01-06 | Ripresa | Morgan Stanley | Equal-Weight |
| 2022-01-06 | Ripresa | Piper Sandler | Overweight |
| 2021-10-15 | Ripresa | Cowen | Outperform |
| 2021-08-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2021-06-01 | Aggiornamento | Evercore ISI | Underperform → In-line |
| 2021-03-31 | Downgrade | Atlantic Equities | Overweight → Neutral |
| 2021-03-31 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2021-03-03 | Iniziato | Barclays | Underweight |
| 2020-12-22 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2020-12-17 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2020-10-13 | Downgrade | Guggenheim | Buy → Neutral |
| 2020-09-30 | Iniziato | Atlantic Equities | Overweight |
| 2020-09-29 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2020-09-22 | Downgrade | Stifel | Buy → Hold |
| 2020-09-22 | Downgrade | UBS | Buy → Neutral |
| 2020-09-21 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-09-21 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-09-09 | Iniziato | Morgan Stanley | Equal-Weight |
| 2020-08-07 | Downgrade | Evercore ISI | In-line → Underperform |
| 2020-08-07 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2020-07-07 | Downgrade | Guggenheim | Buy → Neutral |
| 2020-04-24 | Downgrade | Citigroup | Buy → Neutral |
| 2020-04-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-01-08 | Iniziato | Wells Fargo | Underweight |
| 2020-01-07 | Iniziato | Citigroup | Buy |
| 2020-01-02 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-11-15 | Iniziato | Stifel | Buy |
| 2019-10-25 | Iniziato | Guggenheim | Buy |
Mostra tutto
Illumina Inc Borsa (ILMN) Ultime notizie
Illumina CEO Sees Big Growth Opportunity in China - marketscreener.com
Illumina Announces Alliance Framework with AstraZeneca, Merck, and Eli Lilly and Company - marketscreener.com
JPM26: Illumina debuts Billion Cell Atlas to drive AI-driven drug discovery - Pharmaceutical Technology
Illumina Produces Midteens Earnings Growth in 2025, Distancing Itself From the Grail Debacle - Morningstar
Canada Next-Generation Sequencing (NGS) Market Analysis and Forecast, 2025-2035, Featuring Illumina, Oxford Nanopore Technologies, Pacific Bioscience of California, MGI Tech Co., QIAGEN and More - GlobeNewswire
Illumina introduces Billion Cell Atlas, genome-wide genetic perturbation dataset - marketscreener.com
Illumina Billion Cell Atlas to accelerate AI, drug discovery - BioWorld MedTech
Illumina Introduces Illumina Billion Cell Atlas To Accelerate AI Drug Discovery - Nasdaq
Illumina unveils dataset to speed up AI-powered drug discovery - Reuters
Illumina introduces billion cell atlas to accelerate AI and drug discovery - marketscreener.com
Illumina Introduces Genetic Perturbation Dataset to Further AI Drug Discovery - marketscreener.com
Illumina launches billion cell atlas to boost AI-driven drug discovery - Investing.com Australia
Illumina reports 5% revenue growth in Q4 2025, flat for full year - Investing.com Australia
Illumina Preliminary Q4, Annual Results Beat Analysts' View - Nasdaq
(ILMN) Illumina Expects 2025 Revenue About $4.34B, vs. FactSet Est of $4.28B - marketscreener.com
Illumina reports preliminary Q4 revenue of $1.15B - MSN
Illumina introduces Billion Cell Atlas to accelerate AI and drug discovery - PR Newswire
Illumina Announces Preliminary Unaudited Financial Results for Q4 and Fiscal Year 2025 - TradingView — Track All Markets
Illumina Announces Preliminary Unaudited Financial Results for Fourth Quarter and Fiscal Year 2025 - PR Newswire
Illumina launches massive cell atlas to fast-track drug discovery - statnews.com
DNA Methylation Sequencing Market Set to Revolutionize - openPR.com
Illumina and PREMIA partner to expand clinical access to CGP in Asia - ANTARA News
Dr Eric Green named Illumina Chief Medical Officer - Medical Buyer
Illumina, Inc. (ILMN): A Closer Look At Its Growth Potential Amidst Analyst Ratings - DirectorsTalk Interviews
Illumina to Announce Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 5, 2026 - WV News
Illumina names former NIH genomics director as chief medical officer - MedTech Dive
Illumina's New Connected Multiomics Platform Set to Boost Its Stock - The Globe and Mail
How Is The Market Feeling About Illumina Inc? - Benzinga
Cathie Wood’s ARK ETF Buys Intellia, Personalised Stock; Sells Illumina By Investing.com - Investing.com Canada
Cathie Wood’s ARK ETF Buys Intellia, Personalised Stock; Sells Illumina - Investing.com
Illumina Inc. Stock Underperforms Friday When Compared To Competitors - 富途牛牛
Will Illumina (ILMN) Beat Estimates Again in Its Next Earnings Report? - sharewise.com
Illumina names former NIH official as medical chief; commercial chief joins Quanterix - Seeking Alpha
Non-Invasive Prenatal Testing Market is expected to generate a revenue of USD 9.83 Billion by 2031, Globally, at 17.01% CAGR: Verified Market Research® - GlobeNewswire Inc.
Former NIH genomics director Eric Green to join Illumina as CMO - statnews.com
Precision Trading with Illumina Inc. (ILMN) Risk Zones - Stock Traders Daily
Will Illumina Inc. stock split again soon2025 EndofYear Setup & Free High Accuracy Swing Entry Alerts - ulpravda.ru
Can Illumina Inc. stock sustain revenue growthQuarterly Profit Review & Long-Term Safe Return Strategies - ulpravda.ru
Illumina Inc. Stock Underperforms Thursday When Compared To Competitors - 富途牛牛
Is Illumina Inc ILU stock a momentum leaderJuly 2025 Big Picture & Fast Gaining Stock Strategy Reports - moha.gov.vn
What makes Illumina Inc. (ILU) stock appealing to growth investorsJuly 2025 Recap & Weekly Momentum Picks - ulpravda.ru
Illumina Appoints Dr. Eric Green as Chief Medical Officer - Illumina
Is It Time To Reassess Illumina (ILMN) After Its Recent Share Price Rebound - Yahoo Finance
China Bans Illumina Sequencer Imports as Trade Tensions Rise - MSN
Biochips Market to Reach US$ 38.53 Billion by 2033, Growing at - openPR.com
Illumina Inc. stock outperforms competitors on strong trading day - MarketWatch
ILMN Stock Price, Forecast & Analysis | ILLUMINA INC (NASDAQ:ILMN) - Chartmill
Illumina launches cloud-based platform for multiomic data analysis By Investing.com - Investing.com Australia
Illumina launches cloud-based platform for multiomic data analysis - Investing.com
Illumina launches powerful software for connected, intuitive, and scalable multiomic analysis - Illumina
New Illumina software helps scientists spot key cancer clues in data - Stock Titan
Illumina Inc Azioni (ILMN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.09%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):